BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19850648)

  • 21. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy.
    Seki N; Hashimoto N; Suzuki Y; Yagui K; Saito Y
    Diabetes Res Clin Pract; 2006 May; 72(2):135-41. PubMed ID: 16290123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
    Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
    J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW; Won YW; Yi JH; Kim HJ
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins on mortality in patients with implantable cardioverter-defibrillators.
    Lai HM; Aronow WS; Kruger A; Desai H; Amin H; Frishman WH; Cohen M; Sorbera C
    Am J Cardiol; 2008 Jul; 102(1):77-8. PubMed ID: 18572039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
    Matsuda H; Hayashi K; Saruta T
    J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial.
    Christian JB; Lapane KL; Hume AL; Eaton CB; Weinstock MA;
    J Natl Cancer Inst; 2008 Sep; 100(17):1223-32. PubMed ID: 18728281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
    Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein A; Andrade SE; Lafata JE; Roblin D; Davis RL; Gunter MJ; Platt R
    Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):55-64. PubMed ID: 16470693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients.
    Hillebrand U; Suwelack BM; Loley K; Lang D; Reuter S; Amler S; Pavenstädt H; Hausberg M; Büssemaker E
    Transpl Int; 2009 Nov; 22(11):1073-80. PubMed ID: 19624495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers decrease the risk of hospitalization secondary to community-acquired pneumonia? A nested case-control study.
    Etminan M; Zhang B; Fitzgerald M; Brophy JM
    Pharmacotherapy; 2006 Apr; 26(4):479-82. PubMed ID: 16553505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin-converting enzyme inhibitor (ACE-I)- and angiotensin receptor blocker (ARB)-related angioedema: a neglected issue in daily practice in Greece.
    Symvoulakis EK; Kyrmizakis DE; Drivas EI; Bizakis J; Velegrakis GA; Lionis C
    Eur J Gen Pract; 2007; 13(4):239-41. PubMed ID: 18324507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
    Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
    Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the early period after kidney transplantation.
    Orlić L; Mikolasević I; Sladoje-Martinović B; Bubić I; Pavletić-Persić M; Racki S
    Coll Antropol; 2013 Sep; 37(3):809-14. PubMed ID: 24308221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers used for the treatment of hypertension appear to be safe in the early posttransplant period.
    Formica RN; Friedman AL; Lorber MI; Bia MJ
    Transplant Proc; 2004 Nov; 36(9):2675-8. PubMed ID: 15621121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease.
    Ferrari P
    Nephrology (Carlton); 2007 Feb; 12(1):81-9. PubMed ID: 17295666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects.
    Katragadda S; Arora RR
    Am J Ther; 2010; 17(1):e11-23. PubMed ID: 20090429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
    Horita Y; Taura K; Taguchi T; Furusu A; Kohno S
    Nephrology (Carlton); 2006 Oct; 11(5):462-6. PubMed ID: 17014562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Arteriovenous fistula patency associated with angiotensin-converting enzyme I/D polymorphism and ACE inhibition or AT1 receptor blockade.
    Moon JY; Jeong KH; Paik SS; Han JJ; Lee SH; Lee TW; Ihm CG; Kim MJ; Chung JH
    Nephron Clin Pract; 2009; 111(2):c110-6. PubMed ID: 19142023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
    Ong HT
    J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
    J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.